このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Automated Reporting System for Biliopancreatic Endoscopic Ultrasound

2026年11月9日 更新者:Qilu Hospital of Shandong University

Development and Prospective Multicenter Validation of an Automated Reporting System for Biliopancreatic Endoscopic Ultrasound

This study aims to develop and prospectively validate an automated reporting system to generate structured preliminary biliopancreatic EUS reports using information collected before and during EUS examinations. System development will be completed before prospective validation, and patients included in system development will be separate from those enrolled in prospective validation.

The prospective multicenter validation will enroll 420 adults undergoing EUS for suspected or confirmed biliopancreatic disease. Each patient will contribute only the first eligible EUS examination. The primary endpoint is the difference in clinical acceptance rates between system-generated preliminary reports and independently prepared manual preliminary reports. Non-inferiority will be assessed using a predefined margin.

A nested endosonographer-reporting substudy will also compare completion time and quality between final reports prepared by endosonographers with and without assistance of a system-generated preliminary report. The study will assess the ability of automated reporting to support accurate and efficient EUS reporting while routine clinical care remains unchanged.

調査の概要

詳細な説明

This study aims to develop and validate an automated reporting system which will generate structured preliminary reports based on preprocedural clinical data, the endosonographer's speech during EUS, EUS videos, and EUS procedural records. System development will be completed before prospective validation, using a dataset separated from the prospective validation cohort.

The prospective multicenter validation will enroll 420 adults undergoing EUS for suspected or confirmed biliopancreatic diseases. Each patient will contribute only the first eligible EUS examination as the index EUS examination. For each index examination, the automated reporting system will generate a system-generated preliminary report, while the examining endosonographer will independently generate the manual preliminary report without AI assistance. Additionally, speech-only preliminary reports and video-only preliminary reports will be generated to explore the contribution of different data inputs.

Each report will be independently assessed by two EUS experts blinded to the report source. Disagreements between the two assessors will be adjudicated by a third expert. Significant clinical corrections are defined as corrections to errors or omissions that could affect lesion localization, diagnosis, or subsequent clinical management; word and format changes alone do not qualify as significant clinical corrections. Clinical acceptance rate is defined as the proportion of all reports generated for enrolled patients that were accepted without significant clinical corrections. The primary endpoint is the difference in clinical acceptance rates between the system-generated preliminary report and the manual preliminary report of the same patient.

Additionally, a predefined nested endosonographer-reporting substudy will use the same cases to compare completion time and quality between final reports prepared by endosonographers with and without assistance of a system-generated preliminary report. Reporting tasks will be randomly assigned to endosonographers. This substudy will evaluate whether the automated reporting system can improve reporting efficiency while maintaining final report quality.

研究の種類

観察的

入学 (推定)

420

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Shandong
      • Jinan、Shandong、中国、250012
        • Qilu Hospital of Shandong University
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳未満 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Adults undergoing EUS for suspected or confirmed biliopancreatic disease at participating hospitals.

説明

Inclusion Criteria:

  1. Patients aged ≥ 18years;
  2. Patients undergoing EUS for suspected or confirmed biliopancreatic disease;
  3. Patients who voluntarily sign the informed consent.

Exclusion Criteria:

  1. Patients who are unable to complete standard scanning due to gastrointestinal obstruction or other reasons;
  2. Patients who underwent surgical treatment or anatomical alterations of the pancreas due to lesions in other thoracic and/or abdominal organs, as well as patients with congenital anatomical abnormalities;
  3. Patients undergoing EUS primarily for therapeutic purpose such as drainage.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
Adults undergoing biliopancreatic endoscopic ultrasound

Adults undergoing EUS for suspected or confirmed biliopancreatic diseases will participate in this study. Each patient provides only the first eligible EUS examination for a prospective validation of the automated reporting system.

The system that integrates preprocedural clinical data, the endosonographer's speech during EUS, EUS videos, and EUS procedural records to generate a system-generated preliminary report. The system-generated preliminary report is generated for research validation after the routine EUS examination and is compared with the endosonographer's independent manual preliminary report. The system does not determine the patient's clinical care.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Difference in clinical acceptance rates between system-generated and manual preliminary reports
時間枠:Preliminary reports from the index EUS examination; assessment within 60 days after EUS.

The within-patient paired difference in clinical acceptance rates, calculated as the rate for system-generated preliminary reports minus that for independently written manual preliminary reports. A report is accepted if it requires no significant clinical corrections-corrections to errors or omissions that could affect lesion localization, diagnosis or clinical management. Failed or blank system-generated reports are classified as not accepted. Non-inferiority is established if the lower limit of the two-sided 95% confidence interval is greater than -5 percentage points.

Preliminary reports from the index EUS examination; assessment within 60 days after EUS.

二次結果の測定

結果測定
メジャーの説明
時間枠
Completeness of the system-generated preliminary reports
時間枠:Index EUS examination; report assessment within 60 days.

In the prospective paired validation, completeness is the proportion of applicable, reference-confirmed items correctly documented in each system-generated preliminary report. Items cover actual examination extent, organ findings, lesion descriptions, and sampling records.

Index EUS examination; report assessment within 60 days.
Number of significant clinical report corrections
時間枠:Index EUS examination; report assessment within 60 days.

In the prospective paired validation, the number of significant clinical corrections required per system-generated preliminary report will be assessed. Reductions and additions relative to the independent manual preliminary report will also be reported.

Index EUS examination; report assessment within 60 days.
Reporting time of the system-generated preliminary report
時間枠:During the first automated report-generation task for the index EUS examination, within 30 days after EUS.

In the prospective paired validation, time is measured from submission of all required inputs-including preprocedural clinical data, the endosonographer's speech, EUS videos, and EUS procedure records-to availability of the first system-generated preliminary report. Failed generation will be reported separately.

During the first automated report-generation task for the index EUS examination, within 30 days after EUS.
Reporting time of the manual preliminary report
時間枠:During the routine reporting session immediately after the index EUS examination, up to 60 days

Description: In the prospective paired validation, time is measured from the endosonographer beginning routine report preparation to submission of the independent manual preliminary report, without AI assistance.

During the routine reporting session immediately after the index EUS examination, up to 60 days
Difference in final report completion time with versus without AI assistance
時間枠:During the assigned reporting tasks for each index EUS examination, up to 60 days

In the randomized endosonographer-reporting substudy, the within-case difference in total time to complete a final report is calculated as unassisted time minus assisted time. Total time includes review of source materials, report generation waiting time where applicable, writing, and verification. This outcome will be formally tested only if non-inferiority of the primary outcome is established.

During the assigned reporting tasks for each index EUS examination, up to 60 days
Quality of final reports in the endosonographer-reporting substudy
時間枠:Final reports from the assigned reporting tasks for each index EUS examination; assessment within 60 days after EUS.

In the randomized endosonographer-reporting substudy, the proportion of final reports accepted without significant clinical corrections will be assessed separately for reports completed with and without access to the system-generated preliminary report. Completeness and clinically important errors and omissions will also be reported.

Final reports from the assigned reporting tasks for each index EUS examination; assessment within 60 days after EUS.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2028年6月30日

研究の完了 (推定)

2028年12月31日

試験登録日

最初に提出

2026年11月4日

QC基準を満たした最初の提出物

2026年11月9日

最初の投稿 (実際)

2026年11月10日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2026SDU-QILU-10

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する